A Clinical Evaluation of a Phakic Intraocular Lens

NCT ID: NCT07291739

Last Updated: 2025-12-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

47 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-08-22

Study Completion Date

2024-10-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to evaluate the clinical performance of the STAAR EVO+ Visian™ Implantable Collamer® Lens with Aspheric (EDOF) Optic as refractive elements to correct or reduce myopia or hyperopia with presbyopia with or without astigmatism.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This prospective, open-labeled, evaluation of clinical performance of the investigational EDOF and Toric EDOF (TEDOF) ICL will be conducted at a single site in the Philippines.

Up to 45-50 subjects (90 eyes) who meet all eligibility criteria will be assigned to one of the following treatment arms, as determined by their preoperative refraction and the Investigator's medical judgement:

* EDOF Toric ICL in both eyes,
* EDOF Toric ICL in one eye and EDOF spherical ICL in fellow eye,
* EDOF spherical ICL in both eyes (up to 20 subjects/40 eyes).

Postoperatively, subjects will undergo ophthalmic examination at regular intervals per the study visit schedule up to 6 months after surgery.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myopia Hyperopia Astigmatism Presbyopia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

EDOF ICL

Eyes treated EVO+ Visian and EVO+ Toric Implantable collamer lens with aspheric optic determined by their preoperative refraction

Group Type OTHER

Implantable Collamer Lens (ICL)

Intervention Type DEVICE

EVO+ Visian Implantable Collamer Lens with Aspheric (EDOF) Optic models VTICM6/VTICH6 (TEDOF ICL) and VICM6/VICH6 (EDOF ICL)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Implantable Collamer Lens (ICL)

EVO+ Visian Implantable Collamer Lens with Aspheric (EDOF) Optic models VTICM6/VTICH6 (TEDOF ICL) and VICM6/VICH6 (EDOF ICL)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Require a spherical lens power from -18.00 Diopters to +3.00 Diopters in both eyes or (in case of EDOF Toric) additional cylindrical lens power between +1.0 to +3.0 Diopters of Cylinder.
* Stable refractive history (+/-0.50 Diopters) as determined by manifest spherical equivalent.
* Requires +1.00 Diopters to +2.50 Diopters reading add in both eyes.
* Minimum distance corrected near visual acuity of 20/40 or worse in both eyes.

Exclusion Criteria

* History of previous ocular surgery.
* Progressive sight threatening disease.
* Low/abnormal endothelial cell density.
* Monocular.
* Serious acute non-ophthalmic disease.
* Pregnant or nursing women, or those who plan to become pregnant over the course of the study.
Minimum Eligible Age

40 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Staar Surgical Company

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Asian Eye Institute

Makati City, , Philippines

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Philippines

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CP18-01

Identifier Type: -

Identifier Source: org_study_id